Prediagnostic biomarkers for early detection of glioma-using case-control studies from cohorts as study approach.
genetic variants
glioblastoma
metabolites
prediagnositic sample
proteins
Journal
Neuro-oncology advances
ISSN: 2632-2498
Titre abrégé: Neurooncol Adv
Pays: England
ID NLM: 101755003
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
entrez:
16
11
2022
pubmed:
17
11
2022
medline:
17
11
2022
Statut:
epublish
Résumé
Understanding the trajectory and development of disease is important and the knowledge can be used to find novel targets for therapy and new diagnostic tools for early diagnosis. Large cohorts from different parts of the world are unique assets for research as they have systematically collected plasma and DNA over long-time periods in healthy individuals, sometimes even with repeated samples. Over time, the population in the cohort are diagnosed with many different diseases, including brain tumors. Recent studies have detected genetic variants that are associated with increased risk of glioblastoma and lower grade gliomas specifically. The impact for genetic markers to predict disease in a healthy population has been deemed low, and a relevant question is if the genetic variants for glioma are associated with risk of disease or partly consist of genes associated to survival. Both metabolite and protein spectra are currently being explored for early detection of cancer. We here present a focused review of studies of genetic variants, metabolomics, and proteomics studied in prediagnostic glioma samples and discuss their potential in early diagnostics.
Sections du résumé
Background
UNASSIGNED
Understanding the trajectory and development of disease is important and the knowledge can be used to find novel targets for therapy and new diagnostic tools for early diagnosis.
Methods
UNASSIGNED
Large cohorts from different parts of the world are unique assets for research as they have systematically collected plasma and DNA over long-time periods in healthy individuals, sometimes even with repeated samples. Over time, the population in the cohort are diagnosed with many different diseases, including brain tumors.
Results
UNASSIGNED
Recent studies have detected genetic variants that are associated with increased risk of glioblastoma and lower grade gliomas specifically. The impact for genetic markers to predict disease in a healthy population has been deemed low, and a relevant question is if the genetic variants for glioma are associated with risk of disease or partly consist of genes associated to survival. Both metabolite and protein spectra are currently being explored for early detection of cancer.
Conclusions
UNASSIGNED
We here present a focused review of studies of genetic variants, metabolomics, and proteomics studied in prediagnostic glioma samples and discuss their potential in early diagnostics.
Identifiants
pubmed: 36380862
doi: 10.1093/noajnl/vdac036
pii: vdac036
pmc: PMC9650466
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ii73-ii80Informations de copyright
© The Author(s) 2022. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.
Références
Hum Genet. 2012 Dec;131(12):1877-88
pubmed: 22886559
Biomed Res Int. 2015;2015:294213
pubmed: 26448931
Cancer Epidemiol. 2021 Dec;75:102043
pubmed: 34564026
Science. 2008 Sep 26;321(5897):1807-12
pubmed: 18772396
Tumour Biol. 2016 Aug;37(8):11065-72
pubmed: 26906551
Neuro Oncol. 2019 Mar 18;21(4):451-461
pubmed: 30624711
Acta Neuropathol. 2015 Jun;129(6):849-65
pubmed: 25720744
Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2174-82
pubmed: 21788435
Acta Oncol. 2010 Aug;49(6):767-75
pubmed: 20446891
Nat Genet. 2017 May;49(5):789-794
pubmed: 28346443
J Natl Cancer Inst. 2011 Nov 2;103(21):1588-95
pubmed: 22010181
Cancer Epidemiol Biomarkers Prev. 2015 May;24(5):810-6
pubmed: 25713050
Nat Commun. 2015 Oct 01;6:8559
pubmed: 26424050
Oncotarget. 2017 Jul 31;8(41):70366-70377
pubmed: 29050286
Neuro Oncol. 2020 Feb 20;22(2):207-215
pubmed: 31665421
Cancers (Basel). 2019 Dec 12;11(12):
pubmed: 31842352
Nat Genet. 2020 Aug;52(8):759-767
pubmed: 32719518
Nat Genet. 2009 Aug;41(8):899-904
pubmed: 19578367
PLoS One. 2017 Jun 8;12(6):e0178705
pubmed: 28594935
Nature. 2019 Dec;576(7785):112-120
pubmed: 31748746
Allergy. 2011 Nov;66(11):1434-41
pubmed: 21726235
Nat Commun. 2020 Jun 23;11(1):3169
pubmed: 32576825
Front Oncol. 2021 Jun 04;11:665235
pubmed: 34150629
Br J Cancer. 2018 Oct;119(7):893-900
pubmed: 30297770
Cancer Med. 2022 Feb;11(4):1016-1025
pubmed: 35029050
Hum Mutat. 2015 Jul;36(7):684-8
pubmed: 25907361
Nature. 2021 Sep;597(7875):175-177
pubmed: 34489576
Acta Oncol. 2016;55(4):401-11
pubmed: 26634384
Cancer Epidemiol Biomarkers Prev. 2007 Apr;16(4):844-6
pubmed: 17416782
Cancers (Basel). 2020 Nov 12;12(11):
pubmed: 33198241
Nature. 2002 Dec 19-26;420(6917):860-7
pubmed: 12490959
Curr Nutr Rep. 2014;3(4):355-363
pubmed: 25383255
Oncotarget. 2016 Jun 14;7(24):37043-37053
pubmed: 27175595
J Natl Cancer Inst. 2012 Aug 22;104(16):1251-9
pubmed: 22855780
Cancer Epidemiol Biomarkers Prev. 2020 Nov;29(11):2332-2342
pubmed: 32856611